T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy

Background Higher levels of tumor-infiltrating lymphocytes (TILs) in breast cancers are associated with increased likelihood of pathologic complete response (pCR) to chemotherapy. DNA methyltransferase inhibitors (DNMTi) can augment immune responses to cancers, decreasing myeloid-derived suppressor...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Monique Williams, Patrick Dillon, Harry D Bear, Andrew S Poklepovic, Maciej Kmieciak, Kandace P McGuire, Xiaoyan Deng, Dipankar Bandyopadhyay, Michael Idowu, Taylor M Jenkins, Giovanni Archer, Lindsey Gwaltney, Daniel Flora, Daniel Stover, Mary Hackney, Masey Ross, Hetal Vachhani, Raphael Louie, Amelia Grover, Tasnim Rahman, Amber Hendrix
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMJ Publishing Group 2025-02-01
Serier:	Journal for ImmunoTherapy of Cancer
Online adgang:	https://jitc.bmj.com/content/13/2/e010294.full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!